As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Ipca Laboratories Ltd. | 3.57% | ₹2,379.47 Cr | 1,23,48,047 |
| Fortis Healthcare Ltd. | 3.49% | ₹2,322.43 Cr | 3,01,61,426 |
| Vishal Mega Mart Ltd. | 3.04% | ₹2,025.16 Cr | 20,05,10,745 |
| L&T Finance Ltd. | 2.71% | ₹1,806.52 Cr | 6,81,70,582 |
| The Federal Bank Ltd. | 2.62% | ₹1,747.48 Cr | 5,50,56,066 |
| Mphasis Ltd. | 2.57% | ₹1,710.48 Cr | 79,39,467 |
| Kei Industries Ltd. | 2.45% | ₹1,632.39 Cr | 36,64,181 |
| GE Vernova T&D India Ltd | 2.45% | ₹1,630.88 Cr | 38,82,119 |
| Dixon Technologies (India) Ltd. | 2.44% | ₹1,626.98 Cr | 12,41,970 |
| Solar Industries India Ltd. | 2.40% | ₹1,602.43 Cr | 8,13,415 |
The fund is rated 3 stars. Investment selection within each industry was a strength, while investment selection within each asset type and balance between returns and downside risk provided some support. Above-average fund size of Rs 66,613.26 crore was a minor drawback.
This fund has a ok track record with Asset Selection/Timing, a good track record with Stock Selection/Timing, a ok risk-reward ratio. It is important to note, however, that this fund has a 66613.263 AUM and a 1.509 expense ratio. Considering all these factors, we have rated this fund as 3.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 5 Nov 2026
As of 31 Oct 2026
Long term capital growth. Investment in equity & equity related securities predominantly in mid cap companies.
The scheme seeks to generate long-term capital appreciation from a portfolio of equity and equity related securities, by investing predominantly in mid companies.
Exit load for units in excess of 10% of the investment,1% will be charged for redemption within 365 days
Mutual funds are subject to market risk. Read all scheme documents carefully.
